Tvardi Therapeutics Inc.
TVRD | NASDAQ
$1.69
+$0.08 (+4.97%)
Sep 22, 2026, 2:19 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -1.75 | -0.11 | -2.65 | -2.23 | -0.08 | 0.77 |
PEG Ratio | 0.02 | 0 | 0.17 | 0.02 | 0 | n/a |
PS Ratio | n/a | 1.04 | 2.19 | 1.09 | 0.30 | 0.05 |
PB Ratio | 1.52 | -1.62 | -0.74 | -1.02 | 0.03 | 0.03 |
P/FCF Ratio | -1.36 | -0.12 | -0.49 | -2.56 | -0.11 | -1.11 |
P/OCF Ratio | -1.36 | -0.12 | -0.50 | -2.57 | -0.11 | -1.18 |
OCF/S Ratio | n/a | -853.54 | -439.14 | -42.67 | -260.93 | -4.06 |
Debt / Equity Ratio | 0.01 | -9.68 | -0.01 | -0.05 | 0.02 | 0.02 |
Quick Ratio | 2.86 | 10.81 | 7.97 | 10.31 | 9.69 | 10.55 |
Current Ratio | 2.86 | 11.03 | 7.97 | 10.31 | 9.84 | 10.55 |
Asset Turnover | n/a | 0.16 | 0.78 | 0.93 | 0.09 | 0.50 |
Interest Coverage | n/a | -6.58 | n/a | -29.18K | n/a | n/a |
Return on Equity | -86.96% | 1.54K% | 190.97% | 189.73% | -38.87% | 3.38% |
Return on Assets | -56.79% | -161.70% | -438.92% | -189.53% | -35.80% | 3.10% |
Return on Invested Capital | -126.49% | -139.18% | -510.20% | -204.43% | -38.53% | 2.12% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | 88.62% | 69.32% | 82.05% | 93.25% | n/a |
Net Profit Margin | n/a | -992.95% | -565.21% | -204.16% | -384.06% | 6.23% |
Pretax Profit Margin | n/a | -998.53% | -565.21% | -204.16% | -384.06% | 5.71% |
Operating Profit Margin | n/a | -781.57% | -579.43% | -209.08% | -386.85% | 3.99% |
FCF Margin | n/a | -868.19% | -450.46% | -42.79% | -261.10% | -4.32% |
EBITDA Margin | n/a | -877.12% | -561.09% | -200.17% | -377.31% | 6.47% |
Add to Watchlist
Select watchlists to add or remove TVRD